Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

NCT05854849 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

244

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Apatinib

Sponsor

Sun Yat-sen University